|
||||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
| UDK 616.61-084:616.379-008.64 |
ISSN 035-2899, 37(2012) No 2 p.101-109 |
|||||||||||||||||||||||||||||||||||
|
Review articles Prevention of Diabetic Nephropathy (Prevencija dijabetesne nefropatije) Jelena Pantelić DOM ZDRAVLJA SMEDEREVSKA PALANKA |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
| Summary: Diabetic nephropathy (DN) occurs in 20–40% of patients with diabetes and is the single leading cause of the end-stage renal disease (ESRD). Persistent albuminuria in the range of 30–300mg/24h (microalbuminuria) has been shown to be the stage of incipient diabetic nephropathy in type 1 and in type 2 diabetes. Microalbuminuria is also a well-established marker of increased cardiovascular disease risk. Patients with microalbuminuria who progress to macroalbuminuria (≥ 300 mg/24 h) are likely to progress to ESRD over a period of years. Prevention of diabetes nephropathy has been shown to retard glomerular filtration rate (GFR) decline in the early stage of diabetes nephropathy – the prevention measures are glyceamic control, blood pressure reduction, angiotensin-converting enzyme inhibition, angiotensin receptor antagonism, calcium channel blockade, cholesterol reduction, smoking cessation, erythropoetin therapy and dietary protein restriction. The fact is that the opportunity for the preservation of renal function is the greatest when the intervention is instigated at an early stage. However, the early stage of diabetes nephropathy is frequently unrecognized and accompanied by multiple associated comorbidities including hypertension, renal osteodystrophy, anaemia, sleep apnoea, cardiovascular disease, hyperparathyroidism and malnutrition. Early treatment of these complications of diabetes could considerably postpone the outcomes of diabetes nephropathy. Key words: prevention, diabetes, nephropathy
Napomena:
kompletan tekst rada na srpskom jeziku |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
|
Corresponding Address: Jelena Pantelić Dom zdravlja Smederevska Palanka Kneza Miloša 4, Smederevska Palanka e-mail : dr_jel_pant@yahoo.com |
Paper received: 28.8.2012 Paper accepted: 23.9.2012 Paper Internet issues: 12.11.2012 |
|||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
